The resurgence of the Adora2b receptor as an immunotherapeutic target in pancreatic cancer.

Saved in:
Bibliographic Details
Title: The resurgence of the Adora2b receptor as an immunotherapeutic target in pancreatic cancer.
Authors: Strickland LN; Department of Anesthesiology, Critical Care, and Pain Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States., Faraoni EY; Department of Anesthesiology, Critical Care, and Pain Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States., Ruan W; Department of Anesthesiology, Critical Care, and Pain Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States., Yuan X; Department of Anesthesiology, Critical Care, and Pain Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States., Eltzschig HK; Department of Anesthesiology, Critical Care, and Pain Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States., Bailey-Lundberg JM; Department of Anesthesiology, Critical Care, and Pain Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States.
Source: Frontiers in immunology [Front Immunol] 2023 Apr 28; Vol. 14, pp. 1163585. Date of Electronic Publication: 2023 Apr 28 (Print Publication: 2023).
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1664-3224
DOI:10.3389/fimmu.2023.1163585